Summit Therapeutics

Company Overview

A clinical-stage bioscience company advancing ivonescimab, a novel PD-1/VEGF bispecific antibody licensed from Akeso, alongside a precision antibiotic ridinilazole, targeting major unmet needs in oncology and infectious disease. Summit Therapeutics operates with a dual-focus strategy, pursuing both a transformative oncology asset and a selective antibiotic designed to minimize microbiome disruption. The company has grown significantly in recent years, transitioning from a primarily infectious disease focus toward a broader clinical-stage oncology position.

Headquarters and Global Presence

Summit Therapeutics is headquartered in Miami, Florida, with operational presence extending through its partnership network across the United States. The company retains commercialization rights to ridinilazole in all markets outside Latin America, reflecting an international commercial footprint in development.

Founding and History

Summit Therapeutics was originally incorporated in the United Kingdom and listed on the AIM market of the London Stock Exchange, later transitioning its primary listing and operational focus to the United States. The company built its early pipeline around ridinilazole for Clostridioides difficile infection, supported by US government funding from BARDA. A transformative pivot came with the in-licensing of ivonescimab from Hong Kong-based Akeso, repositioning Summit as a serious oncology contender. A major capital raise of $500 million in October 2025, at $18.74 per share across approximately 26.68 million shares, underscored investor conviction in the new strategic direction.

Therapy Areas and Focus

Summit's primary oncology focus centers on non-small cell lung cancer and other solid tumors, where ivonescimab's dual blockade of PD-1 and VEGF pathways addresses well-established but incompletely met clinical needs. Ridinilazole targets Clostridioides difficile infection, a significant and recurring hospital-acquired infection with high recurrence rates and limited precision treatment options. Both programs address patient populations where current standard-of-care options carry meaningful limitations in efficacy or tolerability.

Technology Platforms and Modalities

Ivonescimab is a bispecific antibody designed to simultaneously block the PD-1 immune checkpoint and VEGF-mediated angiogenesis in a single molecule, potentially delivering synergistic anti-tumor activity beyond what either mechanism achieves alone. This tetrameric structure, developed by Akeso, is differentiated from the combination of a PD-1 inhibitor with a separate anti-VEGF agent by virtue of its coordinated, tumor-localized mechanism. Ridinilazole is a narrow-spectrum oral antibiotic that selectively targets C. difficile while preserving the broader gut microbiome, a mechanism intended to reduce the recurrence that plagues broader-spectrum CDI therapies.

Key Pipeline and Programs

Ivonescimab (SMT112) is Summit's lead oncology asset, a PD-1/VEGF bispecific antibody in-licensed from Akeso for development and commercialization outside Greater China. The pivotal HARMONi-2 trial evaluated ivonescimab against pembrolizumab as a first-line treatment for PD-L1-positive non-small cell lung cancer, with data from this study generating substantial market attention. Summit has also entered into a clinical collaboration with Revolution Medicines, announced in July 2025, to evaluate ivonescimab in combination with Revolution's RAS-targeted therapies across multiple solid tumor settings, expanding the asset's potential indications. Ridinilazole is a Phase III-stage precision antibiotic for CDI; Phase II results highlighted improvements in patient quality of life versus standard-of-care vancomycin, and the program has received ongoing BARDA funding, including an additional $12 million tranche confirmed in June 2024. Eurofarma Laboratórios holds a license for ridinilazole across Latin America, while Summit retains rights in all other geographies.

Recent Developments

In October 2025, Summit completed a $500 million equity raise from leading biotech institutional and individual investors, providing substantial runway to advance its clinical programs. In July 2025, the company announced a clinical collaboration with Revolution Medicines to study ivonescimab alongside RAS inhibitors in solid tumors. Earlier in 2024, Summit out-licensed ridinilazole to Eurofarma for Latin America and received a further $12 million from BARDA for the CDI program. Phase II data for ridinilazole published in mid-2024 demonstrated quality-of-life benefits versus vancomycin, reinforcing the clinical differentiation thesis.

Key Personnel

Maky Zanini serves as Chief Executive Officer and Executive Chair, having co-led Summit's strategic transformation toward oncology and overseen the Akeso licensing transaction. Robert Duggan, a major investor and strategic architect of the company's pivot, has been central to Summit's capital formation and direction. The management team has been instrumental in executing the company's transition from an infectious disease-focused AIM-listed biotech into a US-listed oncology-oriented clinical-stage company.

Strategic Partnerships

Summit's most consequential partnership is its exclusive license from Akeso for ivonescimab outside Greater China, forming the commercial and clinical backbone of the company's oncology strategy. In July 2025, Summit entered a clinical collaboration with Revolution Medicines to explore ivonescimab in combination with RAS-targeted therapies across solid tumor indications. On the infectious disease side, Eurofarma Laboratórios holds a regional license for ridinilazole across Latin America, while Summit retains global rights elsewhere.

FAQ Section